Literature DB >> 28351891

Squamous Cell Tumors Recruit γδ T Cells Producing either IL17 or IFNγ Depending on the Tumor Stage.

Elena Lo Presti1,2, Francesca Toia3, Sebastiano Oieni3, Simona Buccheri4, Alice Turdo5, Laura Rosa Mangiapane5, Giuseppina Campisi6, Valentina Caputo7, Matilde Todaro1,8, Giorgio Stassi5, Adriana Cordova3, Francesco Moschella3, Gaetana Rinaldi9, Serena Meraviglia10,2, Francesco Dieli1,2.   

Abstract

The identification of reciprocal interactions between tumor-infiltrating immune cells and the microenviroment may help us understand mechanisms of tumor growth inhibition or progression. We have assessed the frequencies of tumor-infiltrating and circulating γδ T cells and regulatory T cells (Treg) from 47 patients with squamous cell carcinoma (SCC), to determine if they correlated with progression or survival. Vδ1 T cells infiltrated SSC tissue to a greater extent than normal skin, but SCC patients and healthy subjects had similar amounts circulating. However, Vδ2 T cells were present at higher frequencies in circulation than in the tissue of either cancer patients or healthy donors. Tregs were decreased in the peripheral blood of SCC patients, but were significantly increased in the tumor compartment of these patients. Tumor-infiltrating γδ T cells preferentially showed an effector memory phenotype and made either IL17 or IFNγ depending on the tumor stage, whereas circulating γδ T cells of SCC patients preferentially made IFNγ. Different cell types in the tumor microenvironment produced chemokines that could recruit circulating γδ T cells to the tumor site and other cytokines that could reprogram γδ T cells to produce IL17. These findings suggest the possibility that γδ T cells in SCC are recruited from the periphery and their features are then affected by the tumor microenvironment. Elevated frequencies of infiltrating Vδ2 T cells and Tregs differently correlated with early and advanced tumor stages, respectively. Our results provide insights into the functions of tumor-infiltrating γδ T cells and define potential tools for tumor immunotherapy. Cancer Immunol Res; 5(5); 397-407. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28351891     DOI: 10.1158/2326-6066.CIR-16-0348

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  24 in total

Review 1.  The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?

Authors:  Domenico Galati; Serena Zanotta; Marialuisa Bocchino; Rosaria De Filippi; Antonio Pinto
Journal:  Cancer Immunol Immunother       Date:  2021-01-01       Impact factor: 6.968

2.  Hypoxia regulates the differentiation and anti-tumor effector functions of γδT cells in oral cancer.

Authors:  S K Sureshbabu; D Chaukar; S V Chiplunkar
Journal:  Clin Exp Immunol       Date:  2020-05-18       Impact factor: 4.330

3.  STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.

Authors:  L L Bu; G T Yu; L Wu; L Mao; W W Deng; J F Liu; A B Kulkarni; W F Zhang; L Zhang; Z J Sun
Journal:  J Dent Res       Date:  2017-06-12       Impact factor: 6.116

Review 4.  γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

Authors:  Bruno Silva-Santos; Sofia Mensurado; Seth B Coffelt
Journal:  Nat Rev Cancer       Date:  2019-07       Impact factor: 60.716

Review 5.  Gamma-delta (γδ) T cells: friend or foe in cancer development?

Authors:  Yijing Zhao; Chao Niu; Jiuwei Cui
Journal:  J Transl Med       Date:  2018-01-10       Impact factor: 5.531

Review 6.  Role of Type I and II Interferons in Colorectal Cancer and Melanoma.

Authors:  Simone Di Franco; Alice Turdo; Matilde Todaro; Giorgio Stassi
Journal:  Front Immunol       Date:  2017-07-26       Impact factor: 7.561

Review 7.  Tissue Adaptations of Memory and Tissue-Resident Gamma Delta T Cells.

Authors:  Camille Khairallah; Timothy H Chu; Brian S Sheridan
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

Review 8.  Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.

Authors:  Timm Hoeres; Manfred Smetak; Dominik Pretscher; Martin Wilhelm
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

9.  Tumor-associated neutrophils suppress pro-tumoral IL-17+ γδ T cells through induction of oxidative stress.

Authors:  Sofia Mensurado; Margarida Rei; Telma Lança; Marianna Ioannou; Natacha Gonçalves-Sousa; Hiroshi Kubo; Marie Malissen; Venizelos Papayannopoulos; Karine Serre; Bruno Silva-Santos
Journal:  PLoS Biol       Date:  2018-05-11       Impact factor: 8.029

Review 10.  γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.

Authors:  Elena Lo Presti; Gabriele Pizzolato; Anna Maria Corsale; Nadia Caccamo; Guido Sireci; Francesco Dieli; Serena Meraviglia
Journal:  Front Immunol       Date:  2018-06-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.